Physician profile
Laurie E Katzman
NPI 1881650125
$578.38
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $47.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $179.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $93.34 | 2019 | |
| Novo Nordisk INC | $83.27 | 2019 | |
| Pfizer INC. | $39.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.19 | 2019 | |
| Glaxosmithkline, LLC. | $24.64 | 2019 | |
| Genentech USA, INC. | $24.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.40 | 2019 | |
| Merck Sharp & Dohme LLC | $15.55 | 2019 | |
| Lilly USA, LLC | $11.77 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Katzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.